The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats

Diabetes

Volumn 48, Issue 7, 1999, Pages 1448-1453

  Walker, Adrian B ^a,c   Chattington, Paula D ^a   Buckingham, Robin E ^b   Williams, Gareth ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; MALE; MESENTERIC ARTERY; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ANIMALS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; OBESITY; RATS; RATS, ZUCKER; THIAZOLES; THIAZOLIDINEDIONES; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0032993428     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.7.1448     Document Type: Article

References (53)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988
2. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed pre-diabetic individuals: does the clock for coronary artery disease start ticking before the onset of clinical diabetes? J Am Med Assoc 263:2893-2898, 1990
3. Anderson EA, Hoffmann RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia stimulates both sympathetic neural activation and vasodilatation in normal humans. J Clin Invest 87:2246-2252, 1991
4. De Fronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ: The effect of insulin on renal handling of sodium, potassium and phosphate in man. J Clin Invest 55:845-855, 1975
5. Weidmann P, Ferrari P: Central role of sodium in hypertension in diabetic subjects. Diabetes Care 14:220-232, 1991
6. Baron AD: Hemodynamic actions of insulin. Am J Phys 267 (Endocrinol Metab 30):E187-E202, 1994
7. McNally PG, Lawrence IG, Watt PAC, Hillier C, Burden AC, Thurston H: The effect of insulin on the vascular reactivity of isolated resistance arteries taken from healthy volunteers. Diabetalogia 38:467-473, 1995
8. Walker AB, Savage MW, Dores J, Williams G: Insulin-induced attenuation of noradrenaline-mediated vasoconstriction in resistance arteries from Wistar rats is nitric oxide dependent. Clin Sci 92:147-152, 1997
9. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94:2511-2515, 1994
10. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL: Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 19:621-627, 1992
11. Laakso M, Edelman SV, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest 85: 1844-1852, 1990
12. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41:1076-1083, 1992
13. Walker AB, Dores J, Buckingham RE, Savage MW, Williams G: Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin Sci 93:235-241, 1997
14. Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B: Severe hepatic and peripheral insulin resistance as evidenced by euglycaemic clamps in genetically obese fa/fa rats. Endocrinology 118:674-678, 1986
15. Kurtz TW, Morris RC, Pershadsingh HA: The fatty Zucker rat as a genetic model of obesity and hypertension. Hypertension 13:896-901, 1989
16. Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, Gibbs EM, Kreutter DK: Actions of novel antidiabetic agent englitazone in hyperglycemic, hyperinsulinemic ob/ob mice. Diabetes 39:1218-1227, 1990
17. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
18. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210, 1994
19. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1991
20. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
21. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137: 4189-4195, 1996
22. Szalkowski D, White-Carrington S, Berger J, Zhang B: Antidiabetic thiazo lidinediones block the inhibitory effect of tumour necrosis factor-α on differentiation, insulin-stimulated glucose uptake and gene expression in 3T3-L1 cells. Endocrinology 136:1474-1481, 1995
23. Hotamisligil GS, Budavari A, Murray DL, Spiegelman B: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor α. J Clin Invest 94:1543-1549, 1994
24. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okunu A, Wada M, Fujiwara T, Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 41:75-80, 1993
25. Buckingham RE, Al-Barazanji K, Toseland N, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC: The PPAR-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326-1334, 1998
26. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H: Antihypertensive and vasculo- and reno-protective effects of pioglitazone in genetically obese rats. Am J Physiol 272:E989-E996, 1997
27. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hseuh WA: Blood pressure lowering by Pioglitazone: evidence for a direct vascular effect. J Clin Invest 96:354-360, 1995
28. Kaufman LN, Peterson MM, DeGrange LM: Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 44:1105-1109, 1995
29. Buckingham R, Toseland N, Al-Barazanji K, Gee A, Turner N: BRL 49653, a new insulin-sensitizing agent, favorably influences metabolic indices and morphological changes in pancreas of Zucker fatty rats (Abstract). Diabetes 45 (Suppl.2):143A, 1996
30. Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D, Buckingham R, Williams G: Increased feeding in fatty Zucker rats by the thiazolidinedione BRL49653 (Rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 122:1405-1410, 1997
31. Mulvany MJ, Halpern W: Mechanical properties of smooth muscle cells in situ. Nature 260:617-619, 1976
32. Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive rats. Circ Res 41:19-26, 1977
33. Williams G, Pickup J, Clark A, Bowcock S, Cooke E, Keen H: Changes in blood flow close to subcutaneous insulin injection sites in stable and brittle diabetics. Diabetes 32:466-473, 1983
34. Page MMcB, Watkins PJ: Provocation of postural hypotension by insulin in diabetic neuropathy. Diabetes 25:90-95, 1976
35. Feldman RD, Briebier GS: Insulin-mediated vasodilatation: impairment with increased blood pressure and body mass. Lancet 342:707-709, 1993
36. Tooke JE, Lins P-E, Östergren J, Adamson U, Fagrell B: The effects of intravenous insulin infusion on skin microcirculatory flow in type 1 diabetes. Int J Microcirc Clin Exp 4:69-83, 1985
37. Wambach GK, Liu D: Insulin attenuates vasoconstriction induced by noradrenaline, serotonin and potassium chloride in rat mesenteric resistance arteries. J Hypertens 9 (Suppl. 6):S198-199, 1991
38. Vollenwieder P, Tappy L, Randin D, Schneiter P, Jéquier E, Nicod P, Scherrer U: Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 92:147-154, 1993
39. Stout RW, Bierman EL, Ross R: Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 36:319-327, 1975
40. Pfeifle B, Ditschuneit H: Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 20:155-158, 1981
41. Skott P, Vaag A, Bruun NE, Hother-Nielsen O, Gall M-A, Beck-Nielsen H, Parving H-H: Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance. Diabetologia 34:275-281, 1991
42. Tack CJJ, Ong MKE, Lutterman JA, Smits P: Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia 41:569-576, 1998
43. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8:316-320, 1995
44. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Fala BW, the Troglitazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
45. Liu S-Y, Lu X, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen X, Angel A, Choy PC, Man RYK: Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium-dependent relaxation. Cardiovas Res 28:1476-1481, 1994
46. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230-1239, 1997
47. Shinozaki K, Nishio Y, Okamura T, Hidaka H, Maeno Y, Toda N, Kashiwagi A: Troglitazone improves endothelium-dependent vasorelaxation of aorta in insulin resistant rats (Abstract). Diabetes 47 (Suppl. 1): A116, 1998
48. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rate. Am J Physiol 265:R726-R732, 1993
49. Law RE, Meehan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimai hyperplasia. J Clin Invest 98:1897-1905, 1996
50. Fujiwara T, Oshawa T, Miyamoto M, Ushiyama S, Matsuda K, Horikoshi H: Troglitazone (CS-045) acutely increases skin blood flow in dexamethasone-induced diabetic obese Zucker rats and normal rats (Abstract). Diabetes 44 (Suppl. 1):72A, 1995
51. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD: Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24:170-175, 1994
52. 2+ currents and not endothelial nitric oxide production. Diabetes 46:659-664, 1997
53. Walker AB, Naderali EK, Chatttington PD, Buckingham RE, Williams G: Differential vasoactive effects of the insulin-sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47:810-814, 1998